Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA1986 July 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:	
Reg No:	First Names:	First Names:	
Name:	Surname:	Surname:	
Address:	DOB:	Address:	
	Address:		
Fax Number:		Fax Number:	
Alglucosidase Alfa			
Initial application Applications only from a metabolic physician. Approvals valid for 12 months.  Prerequisites(tick boxes where appropriate)			
The patient is aged up to 24 months at the time of initial application and has been diagnosed with infantile Pompe disease			
Diagnosis confirmed by documented deficiency of acid alpha-glucosidase by prenatal diagnosis using chorionic villus biopsies and/or cultured amniotic cells  Documented deficiency of acid alpha-glucosidase, and urinary tetrasaccharide testing indicating a diagnostic elevation of			
glucose tetrasaccharides  or			
Documented deficiency of acid alpha-glucosidase, and documented molecular genetic testing indicating a disease-causing mutation in the acid alpha-glucosidase gene (GAA gene)  or			
Documented urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides, and molecular genetic testing indicating a disease-causing mutation in the GAA gene			
and Patient has not required long-term invasive ventilation for respiratory failure prior to starting enzyme replacement therapy (ERT)			
Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by ERT or might be			
reasonably expected to compromise a response to ERT  and  Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks			
Aigiticositidase alia to be administered at doses no greater than 20 mg/kg every 2 weeks			
Renewal			
Current approval Number (if known):			
Applications only from a metabolic physician. Approvals valid for 12 months.  Prerequisites(tick boxes where appropriate)			
	The treatment remains appropriate for the patient and the patient is benefiting from treatment		
	Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks		
Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates  and			
	Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by ERT		
	Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT and		
There is no evidence of life threate ventilation	There is no evidence of life threatening progression of respiratory disease as evidenced by the needed for > 14 days of invasive ventilation		
There is no evidence of new or progressive cardiomyopathy			

I confirm the above details are correct and that in signing this form I understand I may be audited.